Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 14,000 shares of the business’s stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $13.53, for a total transaction of $189,420.00. Following the completion of the sale, the chief financial officer directly owned 69,828 shares of the company’s stock, valued at $944,772.84. The trade was a 16.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, September 28th, Dominic Piscitelli sold 13,400 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.53, for a total transaction of $181,302.00.
• On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $13.50, for a total transaction of $8,100.00.
• On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $13.69, for a total transaction of $1,054,130.00.

Oric Pharmaceuticals Trading Up 0.5%

NASDAQ:ORIC opened at $13.85 on Thursday. Oric Pharmaceuticals, Inc. has a one year low of $7.23 and a one year high of $14.68. The stock has a 50-day simple moving average of $12.94 and a 200 day simple moving average of $10.98.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.02). Equities research analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ORIC has been the subject of a number of research analyst reports. BTIG Research started coverage on Oric Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “buy” rating and a $26.00 price target for the company. Leerink Partners started coverage on Oric Pharmaceuticals in a research report on Monday, October 5th. They set an “outperform” rating and a $26.00 price target on the stock. JPMorgan Chase & Co. raised their price objective on Oric Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. HC Wainwright raised their price objective on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Fourteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.17.

Institutional Investors Weigh In On Oric Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantinno Capital Management LP lifted its holdings in Oric Pharmaceuticals by 9.3% in the first quarter. Quantinno Capital Management LP now owns 25,526 shares of the company’s stock worth $323,000 after acquiring an additional 2,170 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Oric Pharmaceuticals by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 190,470 shares of the company’s stock valued at $2,413,000 after acquiring an additional 2,549 shares during the period. Integrated Wealth Concepts LLC acquired a new position in Oric Pharmaceuticals in the second quarter valued at approximately $38,000. Quantbot Technologies LP bought a new position in shares of Oric Pharmaceuticals during the second quarter valued at approximately $46,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Oric Pharmaceuticals by 17.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,470 shares of the company’s stock valued at $687,000 after purchasing an additional 9,231 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.